Urology
Astellas Europe has a solid and proven track record in Urology, making it a Global Category Leader (GCL) in this field of medicine. This is due to an impressive portfolio of drugs for Urology.
New medicines for use in Urology are currently under evaluation through a major R&D programme. By focusing our resources and expertise in areas of Urology that still have unmet medical needs, Astellas Europe leads the way in developing pioneering treatments for conditions such as Benign Prostatic Hyperplasia (BPH), Prostate Cancer, and Overactive Bladder (OAB), offering hope to patients.
Through our commitment to continuing research, support, and understanding, we are working to identify and develop innovative solutions to the current challenges in Urology.
